Pharma Focus Asia
KP - Choose our fully recyclable blister films

New Antibiotic by Merck that Fights Bacteria

In the present drug discovery scenario, there are very few pharmaceutical companies who invest in research into antibiotics, as majority prefer to focus on profitable drugs for chronic diseases. Most drugs were developed 50 years ago and older antibiotics have lost their effect as the bacteria have become resistant to them.

Merck has developed an antibiotic – platensimycin, which could be used to fight bacteria such as MRSA, resistant to current antibiotics such as oxazolidinone and streptogrami. The antibiotic inhibits an enzyme called FabF, used in fatty acid formations that are building blocks of cell membranes and surfaces for bacteria.

The research team at Merck checked 250,000 natural compounds to discover potential antibacterials. Their research narrowed to platensimycin- a small bacterial molecule made by a bug in South Africa. The antibiotic has been tested on mice and did not have any toxic effect on them. The antibiotic still has to undergo various clinical phases before it can be made commercially viable.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS